Total Payments
$33,948
2024 Payments
$638.93
Companies
35
Transactions
254
Medicare Patients
1,223
Medicare Billing
$534,852
Payment Breakdown by Category
Other$11,960 (35.2%)
Consulting$8,800 (25.9%)
Food & Beverage$5,484 (16.2%)
Research$5,343 (15.7%)
Travel$2,317 (6.8%)
Education$43.97 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,800 | 5 | 28.9% |
| Consulting Fee | $8,800 | 3 | 25.9% |
| Food and Beverage | $5,484 | 229 | 16.2% |
| Unspecified | $5,343 | 3 | 15.7% |
| Travel and Lodging | $2,317 | 10 | 6.8% |
| Honoraria | $2,160 | 1 | 6.4% |
| Education | $43.97 | 3 | 0.1% |
Payments by Type
General
$28,605
251 transactions
Research
$5,343
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fresenius USA Marketing, Inc. | $9,940 | 24 | $0 (2024) |
| BAXTER HEALTHCARE | $8,114 | 15 | $0 (2019) |
| Novo Nordisk AS | $5,069 | 2 | $0 (2020) |
| Amgen Inc. | $3,178 | 36 | $0 (2024) |
| Horizon Therapeutics plc | $2,349 | 11 | $0 (2023) |
| Vifor Pharma, Inc. | $2,038 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $639.43 | 33 | $0 (2024) |
| Relypsa, Inc. | $322.35 | 19 | $0 (2020) |
| AKEBIA THERAPEUTICS INC | $306.98 | 15 | $0 (2023) |
| Eli Lilly and Company | $274.54 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $638.93 | 23 | Amgen Inc. ($174.96) |
| 2023 | $1,055 | 32 | Eli Lilly and Company ($274.54) |
| 2022 | $571.13 | 20 | Amgen Inc. ($264.82) |
| 2021 | $2,564 | 40 | Vifor Pharma, Inc. ($1,943) |
| 2020 | $9,532 | 20 | Novo Nordisk AS ($5,069) |
| 2019 | $8,865 | 49 | BAXTER HEALTHCARE ($8,091) |
| 2018 | $2,898 | 28 | Fresenius USA Marketing, Inc. ($2,454) |
| 2017 | $7,823 | 42 | Fresenius USA Marketing, Inc. ($7,322) |
All Payment Transactions
254 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.14 | General |
| 11/01/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.04 | General |
| 10/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: Diabetes | ||||||
| 10/25/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Cardiology | ||||||
| 09/19/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $103.13 | General |
| Category: Nephrology | ||||||
| 09/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.68 | General |
| Category: DIABETES | ||||||
| 08/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.60 | General |
| Category: Diabetes | ||||||
| 08/16/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/26/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: Nephrology | ||||||
| 07/19/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/12/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Inflammation | ||||||
| 07/02/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Nephrology | ||||||
| 06/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.68 | General |
| Category: DIABETES | ||||||
| 06/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/07/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: Inflammation | ||||||
| 05/17/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $29.28 | General |
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/23/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: DIABETES | ||||||
| 03/08/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: Hyperkalemia | ||||||
| 03/07/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Phosphate binder for ESRD | ||||||
| 02/07/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: Genetic Disease | ||||||
| 12/15/2023 | Amgen Inc. | Parsabiv (Drug), TAVNEOS | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: Nephrology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| COR-001-02 | Novo Nordisk AS | $5,069 | 2 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $274.54 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 271 | 1,038 | $229,000 | $95,108 |
| 2022 | 13 | 307 | 947 | $235,690 | $112,431 |
| 2021 | 13 | 312 | 798 | $318,350 | $157,339 |
| 2020 | 13 | 333 | 895 | $425,510 | $169,974 |
Total Patients
1,223
Total Services
3,678
Medicare Billing
$534,852
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 26 | 160 | $104,000 | $50,421 | 48.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 70 | 168 | $42,000 | $11,481 | 27.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 20 | 35 | $19,250 | $9,128 | 47.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 25 | 161 | $19,320 | $7,189 | 37.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 20 | 125 | $18,750 | $5,946 | 31.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 19 | 151 | $13,590 | $5,630 | 41.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 21 | 90 | $9,000 | $3,171 | 35.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 56 | 134 | $1,340 | $1,093 | 81.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 14 | 14 | $1,750 | $1,050 | 60.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 34 | 225 | $123,750 | $62,219 | 50.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 59 | 147 | $36,750 | $15,441 | 42.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 20 | 30 | $19,500 | $9,955 | 51.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 22 | 115 | $10,350 | $6,617 | 63.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 25 | 106 | $12,720 | $4,962 | 39.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 15 | 68 | $10,200 | $3,661 | 35.9% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 13 | 18 | $7,740 | $3,422 | 44.2% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 18 | 70 | $7,000 | $2,652 | 37.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 19 | $3,230 | $1,399 | 43.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 14 | 14 | $1,750 | $983.50 | 56.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 15 | 15 | $900.00 | $529.35 | 58.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 45 | 105 | $1,050 | $311.25 | 29.6% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2022 | 15 | 15 | $750.00 | $280.13 | 37.4% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 46 | 194 | $106,700 | $54,310 | 50.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 44 | 143 | $92,950 | $48,074 | 51.7% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 12 | 85 | $46,750 | $23,410 | 50.1% |
About Dr. Robert Lynn, MD
Dr. Robert Lynn, MD is a Internal Medicine healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1851388862.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Lynn, MD has received a total of $33,948 in payments from pharmaceutical and medical device companies, with $638.93 received in 2024. These payments were reported across 254 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($9,800).
As a Medicare-enrolled provider, Lynn has provided services to 1,223 Medicare beneficiaries, totaling 3,678 services with total Medicare billing of $534,852. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Bronx, NY
- Active Since 10/04/2005
- Last Updated 05/26/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1851388862
Products in Payments
- Velphoro (Drug) $9,940
- Renal - HD (Device) $7,996
- KRYSTEXXA (Biological) $2,349
- EPOGEN (Biological) $2,000
- Veltassa (Drug) $535.64
- Parsabiv (Drug) $509.52
- LOKELMA (Drug) $464.67
- Aranesp (Biological) $273.15
- Auryxia (Drug) $273.13
- Parsabiv (Biological) $224.02
- AURYXIA (Drug) $174.53
- ACTHAR (Biological) $167.22
- JARDIANCE (Drug) $146.62
- FARXIGA (Drug) $132.42
- LUPKYNIS (Drug) $117.46
- COVERA (Device) $102.51
- TAVNEOS (Drug) $100.85
- Rayaldee (Drug) $96.37
- Renal - Non Product Related (Biological) $94.43
- Kerendia (Drug) $84.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bronx
Timothy Kanter, M.d, M.D
Internal Medicine — Payments: $865,160
Internal Medicine $865,160
Dr. Jason Leider, M.d, M.D
Internal Medicine — Payments: $759,257
Internal Medicine $759,257
Bulent Atac, Md, MD
Internal Medicine — Payments: $654,500
Internal Medicine $654,500
Shervin Mortazavi, M.d, M.D
Internal Medicine — Payments: $402,598
Internal Medicine $402,598
Dr. Elizabeth Jenny-Avital
Internal Medicine — Payments: $176,355
Internal Medicine $176,355
Vivek Gumaste, M.d, M.D
Internal Medicine — Payments: $163,229
Internal Medicine $163,229